We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Gain Therapeutics Inc (GANX) USD0.0001

Sell:$4.03 Buy:$4.28 Change: $0.11 (2.76%)
Market closed |  Prices as at close on 10 August 2022 | Switch to live prices |
Change: $0.11 (2.76%)
Market closed |  Prices as at close on 10 August 2022 | Switch to live prices |
Change: $0.11 (2.76%)
Market closed |  Prices as at close on 10 August 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gain Therapeutics, Inc. is a biotechnology company that is developing small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders (LSDs), central nervous system disorders (CNS), metabolic disorders, and oncology. It uses its platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover allosteric sites to modulate protein and identify small molecules that bind these sites to modulate protein function, and treat the underlying cause of the disease. Its pipeline includes its Structurally Targeted Allosteric Regulators (STARs), which develop a pipeline of small molecule drug candidates to address complex diseases. It is evaluating the STARs for the treatment of Gaucher and Parkinson's disease in neuronal cells derived induced pluripotent stem cells (iPSCs) of a patient with Gaucher disease that contained the disease-causing mutation of the GBA1 gene and from iPSCs of a healthy donor with a normal GBA1 gene.

Contact details

4800 Hampden Lane, Suite 200
United States
+1 (301) 5001556

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$50.03 million
Shares in issue:
11.88 million
United States
US dollar

Key personnel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.